Q-omics provides the consensus-scored HOXB3 profile across patient tissues and cancer cell-line models. HOXB3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HOXB3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HOXB3 RNA expression shows 18,950 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KIRC, and DLBC as cancer lineages where HOXB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXB3 survival associations across molecular data types. HOXB3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXB3 RNA expression–survival associations across cancer types. High HOXB3 expression shows unfavorable associations in ACC, LGG, UVM and KIRP, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for HOXB3 RNA expression.
This table summarizes HOXB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXB3 shows lower tumor expression in KIRC and higher tumor expression in COAD, BLCA, LUSC, LIHC and CHOL. The KIRC box plot shows higher HOXB3 RNA expression in normal versus tumor tissue (log2 FC = −1.526, t-test p < 0.001).
This table shows molecular features associated with HOXB3 in patient tissues and cancer cell lines. In patient samples, HOXB3 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
